Abbas, Hosna Hasan; Al Mosawy, Karrar Kadim published an article in 2020, the title of the article was Overview of chronic myeloid leukemia patients in the holy city of Karbala.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile And the article contains the following content:
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by presence of Philadelphia chromosome. Over time CML treatment has change dramatically; especially when Tyrosine Kinase Inhibitor (TKI) introduced, which significantly increase survival and improve quality of life for all patients especially when its associated with good drug adherence and sequential response monitoring to TKI. To study the characteristics of CML patient’s in the Holy City of Karbala and the outcome of Tyrosine Kinase Inhibitor in control of their disease. The present descriptive study included 56 patients, conducted in Al Imam Al Hussein Hematol./Oncol. center at the Holy city of Karbala in Iraq from June 2017 – June 2018. Data from patients with CML were collected and critically analyzed for the demog. data, type of treatment they used and their compliance to drug. The median age was 46 years; male-to-female ratio was 1.24:1. 96.4% patients were diagnosed in chronic phase of their disease. Major mol. response achieved in 79% (27/34) of patients on Gleevec. 37.5% patients were switch to Tasigna after Imatinib resistant or intolerance, 52% of them achieved major mol. response. Drug adherence found in 68% (38/56) patients. CML slightly male predominance, diagnosed at age younger than that report in the United States and Europe, response to TKI nearly similar to that report in international study. Drug adherence and sequential monitoring of patients can improve therapeutic effect of TKI therapy. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
The Article related to chronic myeloid leukemia patients holy city karbala, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics